Literature DB >> 26024799

Therapeutics targeting the inflammasome after central nervous system injury.

Juan Pablo de Rivero Vaccari1, W Dalton Dietrich2, Robert W Keane3.   

Abstract

Innate immunity is part of the early response of the body to deal with tissue damage and infections. Because of the early nature of the innate immune inflammatory response, this inflammatory reaction represents an attractive option as a therapeutic target. The inflammasome is a component of the innate immune response involved in the activation of caspase 1 and the processing of pro-interleukin 1β. In this article, we discuss the therapeutic potential of the inflammasome after central nervous system (CNS) injury and stroke, as well as the basic knowledge we have gained so far regarding inflammasome activation in the CNS. In addition, we discuss some of the therapies available or under investigation for the treatment of brain injury, spinal cord injury, and stroke.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26024799      PMCID： PMC4643411          DOI： 10.1016/j.trsl.2015.05.003

Source DB:  PubMed          Journal:  Transl Res        ISSN： 1878-1810            Impact factor:   7.012


  110 in total

1.  The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response.

Authors:  Alberto Baroja-Mazo; Fatima Martín-Sánchez; Ana I Gomez; Carlos M Martínez; Joaquín Amores-Iniesta; Vincent Compan; Maria Barberà-Cremades; Jordi Yagüe; Estibaliz Ruiz-Ortiz; Jordi Antón; Segundo Buján; Isabelle Couillin; David Brough; Juan I Arostegui; Pablo Pelegrín
Journal:  Nat Immunol       Date:  2014-06-22       Impact factor: 25.606

Review 2.  P2X receptors as drug targets.

Authors:  R Alan North; Michael F Jarvis
Journal:  Mol Pharmacol       Date:  2012-12-19       Impact factor: 4.436

3.  A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury.

Authors:  W P Coleman; D Benzel; D W Cahill; T Ducker; F Geisler; B Green; M R Gropper; J Goffin; P W Madsen; D J Maiman; S L Ondra; M Rosner; R C Sasso; G R Trost; S Zeidman
Journal:  J Spinal Disord       Date:  2000-06

4.  Exosome-mediated inflammasome signaling after central nervous system injury.

Authors:  Juan Pablo de Rivero Vaccari; Frank Brand; Stephanie Adamczak; Stephanie W Lee; Jon Perez-Barcena; Michael Y Wang; M Ross Bullock; W Dalton Dietrich; Robert W Keane
Journal:  J Neurochem       Date:  2015-03-01       Impact factor: 5.372

5.  Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome: clinical article.

Authors:  Stephanie Adamczak; Gordon Dale; Juan Pablo de Rivero Vaccari; M Ross Bullock; W Dalton Dietrich; Robert W Keane
Journal:  J Neurosurg       Date:  2012-10-12       Impact factor: 5.115

6.  Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine.

Authors:  Edward C Keystone; Millie M Wang; Mark Layton; Sally Hollis; Iain B McInnes
Journal:  Ann Rheum Dis       Date:  2012-10       Impact factor: 19.103

Review 7.  Modulation of immune signalling by inhibitors of apoptosis.

Authors:  Shawn T Beug; Herman H Cheung; Eric C LaCasse; Robert G Korneluk
Journal:  Trends Immunol       Date:  2012-07-24       Impact factor: 16.687

Review 8.  Pattern recognition receptors and central nervous system repair.

Authors:  Kristina A Kigerl; Juan Pablo de Rivero Vaccari; W Dalton Dietrich; Phillip G Popovich; Robert W Keane
Journal:  Exp Neurol       Date:  2014-08       Impact factor: 5.330

Review 9.  Spinal cord injury: a review of current therapy, future treatments, and basic science frontiers.

Authors:  Abhay K Varma; Arabinda Das; Gerald Wallace; John Barry; Alexey A Vertegel; Swapan K Ray; Naren L Banik
Journal:  Neurochem Res       Date:  2013-03-06       Impact factor: 3.996

10.  NLRP3 inflammasome contributes to inflammation after intracerebral hemorrhage.

Authors:  Qingyi Ma; Sheng Chen; Qin Hu; Hua Feng; John H Zhang; Jiping Tang
Journal:  Ann Neurol       Date:  2014-01-02       Impact factor: 10.422
View more
  36 in total

Review 1.  Danger Signals and Inflammasomes: Stress-Evoked Sterile Inflammation in Mood Disorders.

Authors:  Monika Fleshner; Matthew Frank; Steven F Maier
Journal:  Neuropsychopharmacology       Date:  2016-07-14       Impact factor: 7.853

Review 2.  When Pain Hurts: Nociceptive Stimulation Induces a State of Maladaptive Plasticity and Impairs Recovery after Spinal Cord Injury.

Authors:  James W Grau; Yung-Jen Huang; Joel D Turtle; Misty M Strain; Rajesh C Miranda; Sandra M Garraway; Michelle A Hook
Journal:  J Neurotrauma       Date:  2016-12-20       Impact factor: 5.269

3.  Inflammatory Biomarkers of Traumatic Brain Injury.

Authors:  Nathan H Johnson; Roey Hadad; Ruby Rose Taylor; Javier Rodríguez Pilar; Osman Salazar; Juan Antonio Llompart-Pou; W Dalton Dietrich; Robert W Keane; Jon Pérez-Bárcena; Juan Pablo de Rivero Vaccari
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-25

4.  Erythropoietin Enhances Post-ischemic Migration and Phagocytosis and Alleviates the Activation of Inflammasomes in Human Microglial Cells.

Authors:  Eren Arik; Ole Heinisch; Michaela Bienert; Lara Gubeljak; Alexander Slowik; Arno Reich; Jörg B Schulz; Thomas Wilhelm; Michael Huber; Pardes Habib
Journal:  Front Cell Neurosci       Date:  2022-06-24       Impact factor: 6.147

Review 5.  Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders.

Authors:  Ebrahim Haroon; Andrew H Miller; Gerard Sanacora
Journal:  Neuropsychopharmacology       Date:  2016-09-15       Impact factor: 7.853

6.  Anti-inflammatory interventions-what has worked, not worked, and what may work in the future.

Authors:  Fatemeh Fattahi; Peter A Ward
Journal:  Transl Res       Date:  2015-08-14       Impact factor: 7.012

Review 7.  Neural-respiratory inflammasome axis in traumatic brain injury.

Authors:  Nadine Kerr; Juan Pablo de Rivero Vaccari; W Dalton Dietrich; Robert W Keane
Journal:  Exp Neurol       Date:  2019-10-15       Impact factor: 5.330

8.  Age-Dependent Microglial Response to Systemic Infection.

Authors:  Brianna Cyr; Juan Pablo de Rivero Vaccari
Journal:  Cells       Date:  2021-04-28       Impact factor: 6.600

9.  Ginsenoside Rg1 alleviates lipopolysaccharide-induced neuronal damage by inhibiting NLRP1 inflammasomes in HT22 cells.

Authors:  Yaodong Zhang; Shixin Ding; Yali Chen; Zhenghao Sun; Junyan Zhang; Yuli Han; Xianan Dong; Zhirui Fang; Weizu Li
Journal:  Exp Ther Med       Date:  2021-05-19       Impact factor: 2.447

10.  Activation of Alpha 7 Cholinergic Nicotinic Receptors Reduce Blood-Brain Barrier Permeability following Experimental Traumatic Brain Injury.

Authors:  Pramod K Dash; Jing Zhao; Nobuhide Kobori; John B Redell; Michael J Hylin; Kimberly N Hood; Anthony N Moore
Journal:  J Neurosci       Date:  2016-03-02       Impact factor: 6.167
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.